Q2 FY2026 EarningsQ2 FY26 missed consensus across all key profitability and revenue metrics. Revenue was $0.41M vs. $1.11M expected, while GAAP Net Loss of $9.01M was significantly wider than the anticipated $5.97M loss. Diluted EPS reached -$1.31 vs. consensus of -$0.88, driven by a 223% YoY surge in operating expenses as the company ramped up R&D for its REYOBIQ platform and expanded its CNSide diagnostic infrastructure. Management warned of substantial doubt regarding the company's ability to continue as a going concern, despite recent capital raises.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cerenome(CNSY) the Revenue is 411 K (-70.43%), Miss estimate;the EBIT is -9.057 M (-488.9%), Miss estimate;the EPS is -1.31 (-313%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B70.43%
0.00B20.14%
-0.00B50.29%
EBITMiss expectations
-0.01B488.88%
-0.01B295.41%
-0.00B193.47%
EPSMiss expectations
-1.31313.01%
-0.88243.09%
-0.430069.92%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf